Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: JF Quinnelly who wrote (5392)	7/30/1998 9:41:00 AM
From: poodle	Read Replies (1) \| Respond to of 9719

ENDOREX Sponsors Research and Development of New CANCER AGENTS At The University of Wisconsin Hmmm... Well, probably misunderstanding. It's about cancer drug... Business Wire - July 30, 1998 08:57 CHICAGO--(BUSINESS WIRE)--July 30, 1997-- Phase I Clinical Data on Perillyl Alcohol Presented at Several Oncology Forums ENDOREX CORPORATION (OTC: ENDR) today announced that its oncology subsidiary, Wisconsin Genetics, Inc., has signed a research agreement with the University of Wisconsin-Madison to sponsor the identification and pre-clinical development of new cancer drugs. These compounds, monoterpenes, will be chemically related to Perillyl alcohol - a cancer drug discovered at the University that was licensed from the Wisconsin Alumni Research Foundation last year to Wisconsin Genetics, Inc.